Monoclonal antibody · Antagonist of Orthoebolavirus zairense glycoprotein · developed by Regeneron Pharmaceuticals
Atoltivimab, maftivimab and odesivimab is a combination of three recombinant human IgG1κ monoclonal antibodies that bind the glycoprotein of Orthoebolavirus zairense, inhibiting the virus. It is studied in Ebola virus disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.
Ebola Virus Disease
Updated Oct 25, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →